The emerging roles of SUMOylation in pulmonary diseases

Molecular Medicine

Review

Zhen Zhang¹  Huifang Tang²  Lingqiao Wang³  Xuyang Zheng³ 

[1] Department of Orthopedics Surgery, The Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, 31000, Hangzhou, Zhejiang, P.R. China;Department of Pharmacology, Zhejiang Respiratory Drugs Research Laboratory, School of Basic Medicial Sciences, Zhejiang University, 310058, Hangzhou, Zhejiang, P.R. China;Department of pediatrics, The Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, 310000, Hangzhou, Zhejiang, P.R. China;

关键词: SUMOylation;    Pneumonia;    cancer;    Hypoxic pulmonary hypertension;    Idiopathic pulmonary fibrosis;   

DOI  :  10.1186/s10020-023-00719-1

 received in 2023-06-20, accepted in 2023-08-22,  发布年份 2023

来源: Springer

【 摘 要 】

Small ubiquitin-like modifier mediated modification (SUMOylation) is a critical post-translational modification that has a broad spectrum of biological functions, including genome replication and repair, transcriptional regulation, protein stability, and cell cycle progression. Perturbation or deregulation of a SUMOylation and deSUMOylation status has emerged as a new pathophysiological feature of lung diseases. In this review, we highlighted the link between SUMO pathway and lung diseases, especially the sumoylated substrate such as C/EBPα in bronchopulmonary dysplasia (BDP), PPARγ in pneumonia, TFII-I in asthma, HDAC2 in chronic obstructive pulmonary disease (COPD), KLF15 in hypoxic pulmonary hypertension (HPH), SMAD3 in idiopathic pulmonary fibrosis (IPF), and YTHDF2 in cancer. By exploring the impact of SUMOylation in pulmonary diseases, we intend to shed light on its potential to inspire the development of innovative diagnostic and therapeutic strategies, holding promise for improving patient outcomes and overall respiratory health.

【 授权许可】

CC BY   
© The Feinstein Institute for Medical Research 2023

【 图 表 】

Fig. 8

Fig. 1